US008178317B2 (12) United States Patent (10) Patent No.: US 8,178,317 B2 Roberts et al. (45) Date of Patent: May 15, 2012 (54) COMPOSITIONS AND METHODS FOR Mende, I. et al., “Oncogenic Transformation Induced by Membrane IDENTIFYING TRANSFORMING AND Targeted AKT2 and AKT3.” Oncogene 20:4419-4423 (2001). TUMIOR SUPPRESSOR GENES Invitation to Pay Additional Fees and Partial International Search Report dated Oct. 14, 2008 from PCT/US2008/062230. (75) Inventors: Thomas M. Roberts, Cambridge, MA Bamford et al., “The COSMIC (Catalogue of Somatic Mutations in (US); Jean Zhao, Brookline, MA (US); Cancer) database and website.” British Journal of Cancer, 91:355 David E. Hill, Arlington, MA (US); 358 (2004). Bartkova et al., “Cyclin D1 protein expression and function in human William C. Hahn, Newton, MA (US); breast cancer.” Int. J. Cancer, 57(3):353-361 (1994). Jesse Boehm, Jamaica Plain, MA (US) Berger et al., “Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells.” Cancer Research, 64:8867-8875 (73) Assignee: Dana-Farber Cancer Institute, Inc., (2004). Boston, MA (US) Boehm et al., “Transformation of Human and Murine Fibroblasts without Viral Oncoproteins.” Molecular and Cellular Biology, *) Notice: Subject to anyy disclaimer, the term of this 25(15):6464-6474 (2005). patent is extended or adjusted under 35 Brown et al., "Control of IkappaB-alphaproteolysis by site-specific, U.S.C. 154(b) by 233 days. signal-induced phosphorylation.” Science, 267: 1485-1488 (1995). Brunet et al., “Constitutively active mutants of MAP kinase kinase (21) Appl. No.: 12/150,941 (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.” Oncogene, 9(11):3379-3387 (1994). (22) Filed: May 1, 2008 Carroll et al., “The TEL/platelet-derived growth factor B receptor (PDGFBR) fusion in chronic myelomonocytic leukemia is a trans (65) Prior Publication Data forming protein that self-associates and activates PDGFBR kinase US 2009/OO47675A1 Feb. 19, 2009 dependent signaling pathways.” Proc. Natl. Acad. Sci. USA, 93: 14845-14850 (1996). Related U.S. Application Data Chudnovsky et al., “Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.” Nat. Genet., 37(7):745 (60) Provisional application No. 60/927,066, filed on May 749 (2005). 1, 2007. Davies et al., “Mutations of the BRAF gene in human cancer.” Nature, 417:949-954 (2002). (51) Int. Cl. Downward, J., “Targeting RAS signalling pathways in cancer CI2P2/06 (2006.01) therapy.” Nat. Rev. Cancer, 3(1):11-22 (2003). C7H 2L/02 (2006.01) Eisenhaber et al., “Post-translational GPI lipid anchor modification of proteins in kingdoms of life: analysis of protein sequence data (52) U.S. Cl. ...................................... 435/69.1:536/23.1 from complete genomes.” Protein Engineering, 14(1):17-25 (2001). (58) Field of Classification Search ................. 536/23.1; Elenbaas et al., “Heterotypic signaling between epithelial tumor cells 435/69.1 and fibroblasts incarcinoma formation.” Exp. Cell Res., 264(1): 169 See application file for complete search history. 184 (2001). Fan et al., “Homo- and Hetero-Oligomerization of the c-Abl Kinase (56) References Cited and Abelson-linteractor-1.” Cancer Research, 63:873-877 (2003). Farrar et al., “Activation of the Raf-1 kinase cascade by U.S. PATENT DOCUMENTS coumermycin-induced dimerization.” Nature, 383:178-181 (1996). Fitzergerald et al., “IKKepsilon and TBK1 are essential components 5,741,899 A * 4/1998 Capon et al. ................. 536,234 of the IRF3 signaling pathway.” Nat. Immunol. 4(5):491-496 (2003). 6,916,846 B2 7/2005 Farrar et al. Garraway et al., “Integrative genomic analyses identify MITF as a 2004/008 1647 A1* 4/2004 Afeyan et al. .............. 424/94.63 lineage Survival oncogene amplified in malignant melanoma.” FOREIGN PATENT DOCUMENTS Nature, 436:117-122 (2005). WO WO-01/83808 11, 2001 (Continued) OTHER PUBLICATIONS Primary Examiner — Karen Carlson Golubet al. 1994: Fusion of PDGF receptor to a novelets-like gene, (74) Attorney, Agent, or Firm — Foley Hoag LLP tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell. 77:307-316. (57) ABSTRACT Maeda et al. 2005, published on-line 2004; Transforming property of TEL-FGFR3 mediated through P13-K in a T-cell lymphoma that Provided herein are nucleic acids, proteins, vectors, cells, Subsequently progressed to aML. Blood 105(5):2115-2123.* kits, devices and methods useful for identifying regulatable Jarvik et al. 1998; Epitope tagging. Annual Review of Genetics. proteins that are able to complement components of cellular 32:601-618. signaling pathways. Also provided are compositions and McWhirter et al. 1993: A coiled-coil oligomerization domain of Bcr methods using these complementing genes directly as mark is essential for the transforming function of Bcr-ABL oncoproteins. ers for cancer diagnosis or prognosis and as targets for anti Molecular and cellular Biology. 13(12): 7587-7595.* Aoki, M. et al., “The AKT Kinase: Molecular Determinants of neoplastic therapeutics. Further provided are methods for Oncogenicity.” Proc. Natl. Acad. Sci. USA95:14950-14955 (1998). using changes caused by expression of the complementing Boehm, J.S. et al., “Integrative Genomic Approaches Identify genes to indirectly identify associated genes to be used as IKBKE as a Breast Cancer Oncogene.” Cell 129:1065-1079 (2007). markers for cancer diagnosis or prognosis and as targets for Jaaro, H. et al., “A Genome Wide Screening Approach for Mem anti-neoplastic therapeutics. brane-Targeted Proteins.” Molec. Cell. Proteomics 4:328-333 (2005). 35 Claims, 20 Drawing Sheets US 8,178,317 B2 Page 2 OTHER PUBLICATIONS Peters et al., “IKKepsilon is part of a novel PMA-inducible IkappaB Golubet al., “Oligomerization of the ABLTyrosine Kinase by the Ets kinase complex.” Mol. Cell, 5(3):513-522 (2000). Protein TEL in Human Leukemia.” Molecular and Cellular Biology, Pinkel et al., “High Resolution analysis of DNA copy number varia 16(8):4107-4116 (1996). tion using comparative genomic hybridization to microarrays.” Nat. Hahn et al., “Creation of human tumour cells with defined genetic Genet., 2002): 207-211 (1998). elements.” Nature, 400:464-468 (1999). Pollocket al., “Regulation of gene expression with synthetic dimer Hahn et al., “Enumeration of the Simian Virus 40 Early Region izers.” Methods Enzymol. 306:263-281 (1999). Elements Necessary for Human Cell Transformation.” Molecular and Ramaswamy et al., “Regulation of G progression by the PTEN Cellular Biology, 22(7):2111-2123 (2002). tumor Suppressor protein is linked to inhibition of the Hanks et al., “The protein kinase family: conserved features and phosphatidylinositol 3-kinase / Akt pathway.” Proc. Natl. Acad. Sci. deduced phylogeny of the catalytic domains.” Science, 241:42-52 USA, 96:2110-2115 (1999). (1988). Rennstam et al., “Patterns of Chromosomal Imbalances Defines Sub Harbury et al., “A switch between two-, three-, and four-stranded groups of Breast Cancer with Distinct Clinical Features and Progno coiled coils in GCN4 leucine zipper mutants.” Science, 262: 1401-7 sis. A Study of 305 Tumors by Comparative Genomic Hybridiza (1993). tion.” Cancer Research, 63.8861-8868 (2003). Harris et al., “Nuclear Accumulation of cRel following C-Terminal Rich et al., “A Genetically Tractable Model of Human Glioma For phosphorylation by TBK1/1KKEe 1.” J. Immunol., 177:2527-2535 mation.” Cancer Research, 61:3556-3560 (2001). (2006). Rivera, V.M.. “Controlling Gene Expression Using Synthetic Hunter, T., "Cooperation between oncogenes.” Cell, 64(2):249-270 Ligands.” Methods, 14(4):421-429 (1998). (1991). Romashkova et al., “NF-kappaB is a target of AKT in anti-apoptotic Johnson et al., “Genetic and biochemical studies of protein PDGF signaling.” Nature, 401:86-90 (1999). N-myristoylation.” Annu. Rev. Biochem, 63:869-914 (1994). Rual et al., "Human ORFeome Version 1.1: A Platform for Reverse Kendall et al., “A Network of Genetic Events Sufficient to Convert Proteomics.” Genome Research, 14:2128-2135 (2004). Normal Human Cells to a Tumorigenic State.” Cancer Res.65:9824 Serrano et al., “Oncogenic ras provokes premature cell senescence 9828 (2005). associated with accumulation of p53 and p16INK4a. Cell, Klippel et al., “Membrane Localization of Phosphatidylinosital 88(5):593-602 (1997). 3-Kinase Is Sufficient to Activate Multiple Signal-Transducing Sharma et al., “Triggering the interferomantiviral response through Kinase Pathways.” Molecular and Cellular Biology, 16(8):4117 an IKK-related pathway.” Science, 300: 1148-1151 (2003). 4127 (1996). Sigal et al., “Amino-terminal basic residues of Src mediate mem Kohn et al., “Akt, a Pleckstrin Homology Domain Containing brane binding through electrostatic interaction with acidic Kinase, Is Activated Primarily by Phosphorylation.” J. Biol. Chem. phospholipids.” Proc. Natl. Acad. Sci. USA,91: 12253-12257 (1994). 271 (36): 21920-21926 (1996). Stanton et al., “Definition of the Human raf Amino-Terminal Regu Li et al., “A novel conditional Akt survival Switch reversibly pro latory Region by Deletion Mutagenesis.” Molecular and Cellular tects cells from apoptosis.” Gene Therapy, 9:233-244 (2002). Biology, 9(2):639-647 (1989). Lundberg et al., “Immortalization and transformation of primary Towler et al., “The biology and enzymology of eukaryotic protein human airway epithelial cells by genetransfer.” Oncogene, 21:4577 acylation.” Annu. Rev. Biochem, 57:69-99 (1988). 4586 (2002). Ung et al., “Heterologous dimerization domains functionally Substi